Comparative Analysis of Salivary Homocysteine and Nitric Oxide Levels in Patients with Polycystic Ovarian Syndrome and Healthy Women-An in vivo Study

Srujana Hemmanur¹, Iffat Nasim²*, Rizwana Aziz³

¹Department of Conservative dentistry and Endodontics, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, India
²Department of Gynecology and Obstetrics, Govt RSRM Hospital, Stanley Medical College, Chennai, India

ABSTRACT

Polycystic ovarian syndrome commonly known as PCOS is a collection of symptoms associated with a poor reproductive health. It is amongst the most common disorders affecting women of reproductive age. It is a multidimensional disorder with unknown aetiology. For diagnosis, currently Rotterdam criteria are widely being used. The aim of the study is to check for the correlation in the amounts of salivary homocysteine and nitric oxide in women with PCOS and healthy controls. The saliva samples were collected by spitting method from 20 women suffering from PCOS (test group) and 20 healthy women with no known disorders (control group). The saliva samples were tested for the presence of homocysteine and nitric oxide and their levels were quantified. In patients with PCOS, salivary homocysteine levels are significantly higher than the control group. However, the salivary nitric oxide levels are significantly lower in the test group when compared to the control group. The results obtained are like many serum and plasma analyses and salivary evaluation can be considered as a chairside technique for the evaluation of the same. However, an expanded study needs to be done to check for any confounding factors.

Keywords: Salivary, Homocysteine, Nitric oxide, PCOS, Syndrome

INTRODUCTION

Polycystic Ovarian syndrome commonly abbreviated as PCOS is a common disorder affecting women of reproductive age [1]. PCOS was first described in the US by Stein and Leventhal in 1935 and has been considered as one amongst the most common endocrine disorders of women [2]. The definition of PCOS given by the National Institutes of Health (NIH) in April 1990 involves (in order of importance): a) hyperandrogenism and/or hyperandrogenemia, 2) ovulatory dysfunction, and 3) exclusion of related disorders such as hyperprolactinemia, thyroid disorders, and congenital adrenal hyperplasia. The definition can be found consistent with the one given by the European Society for Human Reproduction and Embryology and the American Society for Reproductive Medicine in May 2003 in Rotterdam, The Netherlands [2]. Hence, it is a multidimensional disorder in association with endocrinological, reproductive, metabolic, and psychological alterations. It is seen highly amongst women of the reproductive age bracket, has an unknown etiology but a prevalence of 5-10% throughout the world [3]. Though the cause remains unknown, studies strongly indicate genetic components affected by gestational environment, factors modifying lifestyle or both behind the causation of PCOS [4]. A positive familial history of around 17% of respondents with comorbidities including diabetes mellitus, hypertension, hypo/hyperthyroidism, gastrointestinal issues, and subfertility have been reported in a survey conducted in 2018 [5]. Approximately 50-70% of the diagnosed cases have detectable Insulin resistance and hyperinsulinemia which stimulate androgen...
overproduction in ovaries and suppresses sex hormone binding globulin (SBHG) causing cerebrovascular and cardiovascular morbidities [2,6].

For the diagnosis, Rotterdam criteria is widely applied. The criteria suggest that at least two of the following: hyperandrogenism, ovulatory dysfunction and polycystic ovaries must exist. However, other potential causes of hyperandrogenism and dysfunctioning ovaries must be successfully ruled out [7]. The diagnosis can hence be thought to be made through an art of exclusion.

A meta-analysis of 21 studies concluded that dysfunction of endothelium was quite evident in women suffering with PCOS. Nitric oxide and homocysteine in altered concentrations have been found to be associated with endothelial dysfunction [8]. Nitric oxide, a free radical gas molecule, involved in various physiological and pathological processes, is reduced biologically owing to an increased level of superoxide radicals. A limited number of studies indicate that the levels of Nitric Oxide in women with PCOS is questionable [3]. Homocysteine, an amino acid formed by the conversion of methionine to cysteine shows elevated serum concentration in several studies conducted in women with polycystic ovarian syndrome versus healthy controls [3,9,10]. Recently, a study showed the correlation of the serum and salivary levels of homocysteine in patients with Ischaemic Heart Disease (IHD), which helped form the backdrop of the current study [11].

We have numerous highly cited publications on well-designed clinical trials and lab studies [12-27]. This has provided the right platforms for us to pursue the current study. Our aim was to check whether altered amounts of homocysteine and nitric oxide can be found in the salivary samples collected from women with PCOS as compared to healthy women.

MATERIALS AND METHODS

Approval from the Institutional Ethics Committee was obtained before conducting the research. The patients were informed about the procedure, an informed consent was taken, and their identity was promised to not be disclosed.

Inclusion criteria

Patients diagnosed with PCOS and not under medication.

Patients with no other known endocrinological or metabolic disorders.

Age: 20 to 30 years.

Exclusion criteria

Patients under medication for PCOS.

Diagnosed with other known endocrinological or metabolic disorders in association with PCOS.

Age beyond 30 years.

5 ml of saliva samples by spitting method was collected in a test tube and kept in refrigeration at 4°C till the sample wasn’t tested. A total of 40 samples in which 20 samples from the patients diagnosed with PCOS and the remaining 20 samples from healthy women were collected. The collected samples were tested within 24 hours of collection.

Estimation of homocysteine

To 5 μl of saliva sample 20 ml of borate buffer (125 mM boric acid, 4 mM EDTA) was added to make the final volume to 25 μl. 10% (V/V) of tri-n-butyl phosphine in dimethylformamide was added to the sample and vortexed. The resulting mixture was incubated at 4°C for 30 min. Deproteinization was done with 25 μl 10% (W/V) TCA, followed by vortexing and centrifugation at 3000 RPM for 15 min at 4°C. 20 μl of clear supernatant taken in a fresh tube, 4 μl of(1.55N)NAOH was added and vortexed. This tube was kept at 4°C for 10 min and a 50 μl of borate buffer was added and vortexed. Finally, 20 ml of SBDF (ammonium 7-flurobenzo-2-oxa-1, 3-diazole-4sulfonate 1mg/ml in 125 mM boric acid) was added and incubated at 60°C for one hour. The incubation sample was kept at ambient temperature for immediate processing. Standards and controls were prepared simultaneously in a similar manner.

HPLC Chromatography

The sample was injected into a column equilibrated with mobile phase at a flow rate of 1.5 ml per min. The column equilibration time was 15 minutes at ambient temperature. The retention time of each sample was calculated by using standards and calibrators and a calibration curve was plotted for different concentrations. Stationary phase: Octadecylsilane (ODS) 250X4.6
mm column, Mobile phase: 4% acetonitrile in potassium dihydrogen orthophosphate (0.2 M, pH: 2.1), Detector: fluorescent with Ex/Em being 385 nm/515 nm.

Estimation of nitric oxide

In this method, nitrite is first treated with a diazotizing reagent, e.g., sulfanilamide (SA), in acidic media to form a transient diazonium salt. This intermediate was then allowed to react with a coupling reagent, N-naphthyl-ethylenediamine (NED), to form a stable azo compound. The intense purple color of the product allows nitrite assay with high sensitivity. The absorbance of this adduct at 540 nm is linearly proportional to the nitrite concentration in the sample. Salivary samples (50 μl) were transferred to a 96-well enzyme-linked immunosorbent assay plate. Using a multichannel pipettor, 50 μl of the sulfanilamide solution (1% sulfanilamide in 5% phosphoric acid) followed by 50 μl of the naphthyl ethylenediamine solution (0.1% N-naphthyl ethylenediamine) was dispensed to all experimental samples. The samples were incubated at room temperature for 5–10 min. A purple color was observed, and its optical density was measured using a plate reader with 540 nm filter.

Statistical analysis

All the data was entered into Microsoft Excel 2010. Descriptive statistics were expressed as mean ± standard deviation (SD) for each group for salivary homocysteine and salivary nitric oxide (µM/ml). Two groups (Women with PCOS and Healthy subjects) were compared for Salivary Homocysteine and Salivary Nitric Oxide (µM/ml) by Independent ‘t’ Test.

For All the above test p value is considered statistically significant when it was <0.05. The software used was SPSS (Statistical package for Social Sciences) version 17.

RESULTS AND DISCUSSION

Descriptive statistics are mentioned in Table 1. Group 1 Women with PCOS (27.76000 ± 5.083347) and Group 2 Healthy subjects (40.33000 ± 4.926096). X-axis represents the health status of the patient while Y-axis depicts the amount of salivary nitric oxide. It can be inferred that salivary nitric oxide is significantly lower in women with PCOS when compared to the healthy subjects (p value<0.001 with t=-7.941; df=38; Independent ‘t’ test). The current study helps to establish a positive correlation between the levels of salivary homocysteine and nitric oxide in patients with PCOS and healthy women (Figures 1 and 2).

Women with PCOS are seen to have statistically significant greater levels of salivary homocysteine and lesser levels of nitric oxide than the control group (i.e. healthy women). Similar results however through the analysis of serum and plasma were obtained by several authors [3,9,10,28-33]. However, no difference in the levels of serum nitric oxide in PCOS and control group was reported by Nacul et al. [34]. Similarly, Mancini et al. reported no significant difference in the serum homocysteine levels in women with

<table>
<thead>
<tr>
<th>Group</th>
<th>Salivary Homocysteine (mMol/L)</th>
<th>N</th>
<th>Minimum</th>
<th>Maximum</th>
<th>Mean</th>
<th>Std. Deviation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Women with PCOS</td>
<td>20</td>
<td>0.02</td>
<td>0.45</td>
<td>0.2173</td>
<td>0.112832</td>
<td></td>
</tr>
<tr>
<td>Healthy subjects</td>
<td>20</td>
<td>0.01</td>
<td>0.23</td>
<td>0.1165</td>
<td>0.067612</td>
<td></td>
</tr>
<tr>
<td>Women with PCOS</td>
<td>20</td>
<td>14.5</td>
<td>39</td>
<td>27.76</td>
<td>5.083347</td>
<td></td>
</tr>
<tr>
<td>Healthy subjects</td>
<td>20</td>
<td>32</td>
<td>49.2</td>
<td>40.33</td>
<td>4.926096</td>
<td></td>
</tr>
</tbody>
</table>

Table 1: Descriptive Statistics of Salivary Homocysteine (mMol/L) and Nitric Oxide (µM/ml) among two groups (i.e Women with PCOS and healthy subjects). It can be inferred that the mean of salivary homocysteine levels in PCOS patients is greater than that in healthy women. However, the mean of salivary nitric oxide levels in patients with PCOS is less than that of healthy women.
Homocysteine is found to be significantly higher in women with PCOS as compared to control group. It plays an established role in cardiovascular morbidity and mortality as it has prothrombotic and atherogenic properties. The elevated homocysteine levels thus, might play a crucial role in the increased risk of cardiovascular diseases [39] in women suffering from PCOS. High homocysteine levels are independently considered as a risk factor for cardiovascular diseases as the increased oxidative stress in vascular endothelium and activation of platelet aggregation leading to dysfunction of endothelium. Another important finding is that increased homocysteine levels causes decreased availability of nitric oxide in serum that is an early marker of vascular disease. Nitric oxide’s contribution to vessel homeostasis is by the growth, platelet aggregation and leukocyte adhesion to endothelium and inhibition of vascular smooth muscle contraction [40]. The reduced bioavailability of nitric oxide and increased oxidative stress both cause endothelial dysfunction [41] which again directs towards the increased risk of cardiovascular diseases in women with PCOS as a comorbidity.

**CONCLUSION**

The current study found a statistically significant association between salivary homocysteine and nitric oxide levels of patients with PCOS and control group. This evaluation of salivary homocysteine and nitric oxide levels in women with PCOS and healthy subjects could help formulate a chairside test for confirmation of the syndrome along with proper history. Also, the women with a greater risk of cardiovascular diseases could be helped by conforming their lifestyle and prevention or at least delay the occurrence of cardiovascular morbidity. However, the study must be done on a larger population scale to confirm the results and the confounding factors, if any.

**CONFLICT OF INTERESTS**

Nil.
REFERENCES


40. Willis GR, Udiawar M, Evans WD. Detailed characterisation of circulatory nitric oxide and free radical indices—is there evidence for abnormal cardiovascular homeostasis in young women with polycystic ovary syndrome? J Obstetr 2014; 121:1596-1603.